Assets, Current of CITIUS ONCOLOGY, INC. from 31 Dec 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly Assets, Current in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Assets, Current for the quarter ending 31 Dec 2025 was $37,146,844, a 117% increase year-over-year.
- Source SEC data
- View on sec.gov
Assets, Current, Quarterly (USD)
Assets, Current, YoY Quarterly Change (%)
CITIUS ONCOLOGY, INC. Quarterly Assets, Current (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $37,146,844 | +$20,065,363 | +117% | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2025 | $27,542,881 | +$16,574,003 | +151% | 30 Sep 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q2 2025 | $18,309,079 | +$18,268,091 | +44569% | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 |
| Q1 2025 | $18,039,365 | +$17,944,971 | +19011% | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 |
| Q4 2024 | $17,081,481 | +$17,023,281 | +29250% | 31 Dec 2024 | 10-Q | 14 Feb 2025 | 2025 | Q1 |
| Q3 2024 | $10,968,878 | +$3,233,983 | +42% | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q2 2024 | $40,988 | -$420,919 | -91% | 30 Jun 2024 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q1 2024 | $94,394 | -$150,972 | -62% | 31 Mar 2024 | 10-Q | 20 May 2024 | 2024 | Q1 |
| Q4 2023 | $58,200 | -$319,144 | -85% | 31 Dec 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q3 2023 | $7,734,895 | 30 Sep 2023 | 10-K | 27 Dec 2024 | 2024 | FY | ||
| Q2 2023 | $461,907 | 30 Jun 2023 | 10-Q | 16 Aug 2023 | 2023 | Q2 | ||
| Q1 2023 | $245,366 | 31 Mar 2023 | 10-Q | 15 May 2023 | 2023 | Q1 | ||
| Q4 2022 | $377,344 | +$250,922 | +198% | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY |
| Q4 2021 | $126,422 | 31 Dec 2021 | 10-K | 17 Apr 2023 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.